Search Results

You are looking at 191 - 200 of 2,860 items for :

  • Refine by Access: All x
Clear All
Full access

QIM22-191: Expansion of Tobacco Cessation Treatment Within the Stanford Cancer Institute: 6-Month and 24-Month Outcomes

Amy Chieng, Maura Chandler, Cindy Tran, Brittany Pike, Alexandra Liu, LittleDove Faith Rey, Lauren Haruno, Annemarie Jagielo, Amy Pirkl, and Judith J Prochaska

cessation treatment into cancer care. The funding, technical, and peer support from the C3I collaboration was instrumental in extending Stanford’s tobacco treatment service into 20+ clinics across 3 cancer centers. Aim : To report on patient outcomes at 6

Full access

Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced Cancer

Camilla Zimmermann, Ashley Pope, Breffni Hannon, Monika K. Krzyzanowska, Gary Rodin, Madeline Li, Doris Howell, Jennifer J. Knox, Natasha B. Leighl, Srikala Sridhar, Amit M. Oza, Rebecca Prince, Stephanie Lheureux, Aaron R. Hansen, Anne Rydall, Brittany Chow, Leonie Herx, Christopher M. Booth, Deborah Dudgeon, Neesha Dhani, Geoffrey Liu, Philippe L. Bedard, Jean Mathews, Nadia Swami, and Lisa W. Le

—Symptom screening with Targeted Early Palliative care (STEP)—for patients with advanced cancer. Secondary aims were to assess whether STEP identified patients with worse QoL and other patient-reported outcomes (PROs), and whether screen-positive patients who

Full access

NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines

George D. Demetri, Robert S. Benjamin, Charles D. Blanke, Jean-Yves Blay, Paolo Casali, Haesun Choi, Christopher L. Corless, Maria Debiec-Rychter, Ronald P. DeMatteo, David S. Ettinger, George A. Fisher, Christopher D. M. Fletcher, Alessandro Gronchi, Peter Hohenberger, Miranda Hughes, Heikki Joensuu, Ian Judson, Axel Le Cesne, Robert G. Maki, Michael Morse, Alberto S. Pappo, Peter W. T. Pisters, Chandrajit P. Raut, Peter Reichardt, Douglas S. Tyler, Annick D. Van den Abbeele, Margaret von Mehren, Jeffrey D. Wayne, and John Zalcberg

worse outcome than tumors with other KIT or PDGFRA mutant isoforms or with no detectable mutation. 31 – 34 Conversely, KIT exon 11 mutations have been found in mitotically inactive GISTs 1 cm or less in size, suggesting that oncogenic KIT activity

Full access

Multigene Sets for Clinical Application in Glioma

John F. de Groot, Erik P. Sulman, and Kenneth D. Aldape

proliferation and necrosis. 1 Although histologic classification allowed patients with a single disease to be enrolled into clinical trials, and treatment protocols for these patients to be standardized, 2 outcomes were variable and could not be attributed to

Full access

Phase I Clinical Trial of Bendamustine and Bevacizumab for Patients With Advanced Cancer

Apostolia M. Tsimberidou, Alexandra M. Adamopoulos, Yang Ye, Sarina Piha-Paul, Filip Janku, Siqing Fu, David Hong, Gerald S. Falchook, Aung Naing, Jennifer Wheler, Adoneca Fortier, Razelle Kurzrock, and Kenneth R. Hess

study, which reported that the most common toxicities were myelosuppression and gastrointestinal adverse effects. 15 Table 4 Clinical Outcomes by Tumor Type Taking into consideration that patients had a median of 4 prior therapies, and

Full access

QIM20-125: OBESE: Oncologist Based Emphasis on Survivor Education-Physician Driven Weight Loss Counseling and Outcomes in TNBC

Marwah W. Farooqui, Caitlin Carter, Nicholas Gustafson, Saherish Abbasi, Sravani Sagireddy, Kathryn Hockensmith, Amy Stein, Masood Ghouse, and Krishan Srinivasan

Obesity has an association with triple negative breast cancer (TNBC). Healthy diet, weight loss, and exercise have lead to favorable outcomes (overall survival [OS], progression free survival [PFS],quality of life [QOL])in TNBC. We aim to highlight

Full access

Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy

Douglas W. Blayney, Nicole M. Kuderer, Alice Kate Cummings Joyner, John Jarvis, Dominic Nunag, Jasmine Wells, Lan Huang, Ramon Monhanlal, and Gary H. Lyman

immediately preceding the index date, and included patient demographics, comorbidities, and healthcare resource utilization. To investigate the real-world protective benefit of PP G-CSFs, proportions of patients experiencing the primary outcome of FN or

Full access

HSR21-041: Impact of Cardiac Comorbidities on Outcomes After Treatment for Locally Advanced Esophageal Cancer: An Institutional Experience

Luis Aguirre, Jacques Fontaine, Jessica Frakes, Sarah Hoffe, Jose Pimiento, and Rutika Mehta

of cardiac comorbidities impacted the outcomes of patients who underwent trimodality therapy for esophageal cancer. Methods: After IRB approval, we collected data on patients treated at our center for locally advanced disease and received

Full access

EHR-Integrated Patient-Reported Outcomes in Ambulatory Oncology: A Critical Opportunity for Timely and Targeted Palliative Care

Patricia I. Moreno, Frank J. Penedo, Felicia M. Knaul, Carina Oltmann, Michael T. Huber, and Mariana Khawand-Azoulai

The aim of systematic symptom screening and monitoring using patient-reported outcomes (PROs) is to collect actionable data and provide responsive care that is centered around patients’ needs. Recent evidence demonstrates that routine assessment

Full access

Letter to the Editor: Integrating Skeletal Muscle Mass and Radiodensity Improves Outcome Prediction and Correlation in Oncologic Studies

Grant R. Williams, Marc S. Weinberg, and Shlomit S. Shachar

dichotomizing participants as high or low radiodensity, why not integrate these 2 variables into 1 continuous variable? Because both muscle mass and radiodensity are defined independently and both are prognostic of many adverse cancer outcomes, we have proposed